According to a recent LinkedIn post from Xeltis, the company has appointed Elmar Horn as Vice President of Commercial, emphasizing his more than 20 years of international medtech experience and history of bringing vascular technologies to market. The post notes his prior roles at Philips, where he led the peripheral vascular medical device business in the DACH region, and at Avinger as Vice President of International Sales.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights Horn’s involvement in launching image-guided vascular atherectomy systems and coronary stents across multiple countries, suggesting a strong background in commercializing complex cardiovascular devices. This experience may be relevant as Xeltis looks to scale its recently CE-marked aXess vascular access conduit for hemodialysis.
The post suggests that Horn’s appointment is strategically timed to support broader commercialization of aXess, with an explicit reference to bringing the product to patients globally. For investors, this could signal a shift from primarily clinical and regulatory milestones toward market expansion and revenue-focused execution in the European and other international markets.
If Xeltis successfully leverages Horn’s regional expertise from Philips and global sales background from Avinger, the company may improve its go-to-market strategy, channel development, and adoption rates for aXess. This could strengthen Xeltis’s competitive position in the vascular access and cardiovascular device segments, potentially enhancing its long-term growth prospects and attractiveness as a partner or acquisition target.